EMEA-001410-PIP02-17-M02

Key facts

Invented name
Ninlaro
Active substance
Ixazomib
Therapeutic area
Oncology
Decision number
P/0261/2019
PIP number
EMEA-001410-PIP02-17-M02
Pharmaceutical form(s)
  • Powder for solution for injection
  • Capsule (hard)
Condition(s) / indication(s)
Treatment of lymphoid malignancies (excluding multiple myeloma)
Route(s) of administration
  • Intravenous use
  • Oral use
  • Gastric use
Contact for public enquiries
Takeda Pharm A/S

E-mail: bharti.navsariwala@takeda.com​
Tel. +44 (0)20 3116 8000

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating